

Michelle Glass

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5266346/publications.pdf>

Version: 2024-02-01

116
papers

8,899
citations

44042

48
h-index

42364

92
g-index

118
all docs

118
docs citations

118
times ranked

7652
citing authors

#	ARTICLE	IF	CITATIONS
1	Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. <i>Neuroscience</i> , 1997, 77, 299-318.	1.1	903
2	The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease. <i>Neuroscience</i> , 2000, 97, 505-519.	1.1	492
3	Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor. <i>European Journal of Pharmacology</i> , 2000, 396, 141-149.	1.7	480
4	CANNABINOID RECEPTORS AND THEIR ENDOGENOUS AGONISTS. <i>Annual Review of Pharmacology and Toxicology</i> , 1998, 38, 179-200.	4.2	348
5	Concurrent Stimulation of Cannabinoid CB1 and Dopamine D2 Receptors Enhances Heterodimer Formation: A Mechanism for Receptor Cross-Talk?. <i>Molecular Pharmacology</i> , 2005, 67, 1697-1704.	1.0	318
6	Agonist Selective Regulation of G Proteins by Cannabinoid CB ₁ and CB ₂ Receptors. <i>Molecular Pharmacology</i> , 1999, 56, 1362-1369.	1.0	268
7	The Cannabinoid CB2 Receptor as a Target for Inflammation-Dependent Neurodegeneration. <i>Current Neuropharmacology</i> , 2007, 5, 73-80.	1.4	268
8	Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. <i>Nature Communications</i> , 2017, 8, 13958.	5.8	265
9	Loss of cannabinoid receptors in the substantia nigra in huntington's disease. <i>Neuroscience</i> , 1993, 56, 523-527.	1.1	216
10	Pharmacology of Valinate and <i>tert</i> -Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues. <i>ACS Chemical Neuroscience</i> , 2016, 7, 1241-1254.	1.7	214
11	Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. <i>British Journal of Pharmacology</i> , 2007, 152, 583-593.	2.7	209
12	Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1546-1559.	1.7	202
13	Cannabis, cannabinoids and reproduction. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2004, 70, 189-197.	1.0	172
14	Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. <i>ACS Chemical Neuroscience</i> , 2015, 6, 1445-1458.	1.7	167
15	Cannabinoid CB ₁ and CB ₂ Receptor Signaling and Bias. <i>Cannabis and Cannabinoid Research</i> , 2017, 2, 48-60.	1.5	165
16	The endocannabinoid system as a target for the treatment of neurodegenerative disease. <i>British Journal of Pharmacology</i> , 2010, 160, 480-498.	2.7	161
17	Evolutionary origins of the endocannabinoid system. <i>Gene</i> , 2006, 370, 64-74.	1.0	153
18	Delayed onset of huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors. <i>Neuroscience</i> , 2004, 123, 207-212.	1.1	131

#	ARTICLE	IF	CITATIONS
19	CB1 and CB2 receptor-mediated signalling: a focus on endocannabinoids. Prostaglandins Leukotrienes and Essential Fatty Acids, 2002, 66, 161-171.	1.0	128
20	Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neuroscience Letters, 2007, 412, 114-117.	1.0	124
21	Loss of A1 adenosine receptors in human temporal lobe epilepsy. Brain Research, 1996, 710, 56-68.	1.1	120
22	Biased Agonism and Biased Allosteric Modulation at the CB ₁ Cannabinoid Receptor. Molecular Pharmacology, 2015, 88, 368-379.	1.0	118
23	Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal!. Journal of Neuroscience Methods, 2008, 171, 78-86.	1.3	113
24	Cannabinoid receptors are absent in insects. Journal of Comparative Neurology, 2001, 436, 423-429.	0.9	97
25	Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease. Neuroscience, 2009, 163, 456-465.	1.1	97
26	Real-time characterization of cannabinoid receptor 1 (CB ₁) allosteric modulators reveals novel mechanism of action. British Journal of Pharmacology, 2013, 170, 893-907.	2.7	97
27	A new cannabinoid CB ₂ receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury. British Journal of Pharmacology, 2012, 165, 2462-2478.	2.7	90
28	Neurochemical and morphological changes associated with human epilepsy. Brain Research Reviews, 1995, 21, 29-41.	9.1	89
29	Cannabinoid (CB1), GABAA and GABAB receptor subunit changes in the globus pallidus in Huntington's disease. Journal of Chemical Neuroanatomy, 2009, 37, 266-281.	1.0	83
30	Detailed Characterisation of CB2 Receptor Protein Expression in Peripheral Blood Immune Cells from Healthy Human Volunteers Using Flow Cytometry. International Journal of Immunopathology and Pharmacology, 2010, 23, 25-34.	1.0	81
31	The Synthesis and Pharmacological Evaluation of Adamantane-Derived Indoles: Cannabimimetic Drugs of Abuse. ACS Chemical Neuroscience, 2013, 4, 1081-1092.	1.7	80
32	Ca ²⁺ signalling of the CB ₁ receptor and the influence of receptor number. British Journal of Pharmacology, 2017, 174, 2545-2562.	2.7	75
33	Characterization of the Endocannabinoid System in Early Human Pregnancy. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5168-5174.	1.8	72
34	Cannabinoid receptor 2 undergoes Rab5-mediated internalization and recycles via a Rab11-dependent pathway. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 1554-1560.	1.9	72
35	Modulation of Neurotransmission by Cannabinoids in the Basal Ganglia. European Journal of Neuroscience, 1997, 9, 199-203.	1.2	67
36	Terpenoids From Cannabis Do Not Mediate an Entourage Effect by Acting at Cannabinoid Receptors. Frontiers in Pharmacology, 2020, 11, 359.	1.6	66

#	ARTICLE	IF	CITATIONS
37	The role of Cannabinoids in neurodegenerative diseases. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2001, 25, 743-765.	2.5	65
38	Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice. <i>Neuroscience</i> , 2010, 170, 324-336.	1.1	65
39	Differential activation of G-proteins by μ -opioid receptor agonists. <i>British Journal of Pharmacology</i> , 2006, 147, 671-680.	2.7	64
40	Neuroprotective potential of CB ₁ receptor agonists in an <i>in vitro</i> model of Huntington's disease. <i>British Journal of Pharmacology</i> , 2010, 160, 747-761.	2.7	60
41	Cannabinoid Receptors: A brief history and "what's hot".. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 944.	3.0	59
42	Cannabinoid CB1 and CB2 Receptor-Mediated Arrestin Translocation: Species, Subtype, and Agonist-Dependence. <i>Frontiers in Pharmacology</i> , 2019, 10, 350.	1.6	58
43	GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-Arachidonoyl Glycine. <i>PeerJ</i> , 2016, 4, e1835.	0.9	57
44	Cannabinoid receptors in invertebrates. <i>Journal of Evolutionary Biology</i> , 2006, 19, 366-373.	0.8	56
45	Cannabinoid Receptor 1 trafficking and the role of the intracellular pool: Implications for therapeutics. <i>Biochemical Pharmacology</i> , 2010, 80, 1050-1062.	2.0	56
46	Dark Classics in Chemical Neuroscience: δ^9 -Tetrahydrocannabinol. <i>ACS Chemical Neuroscience</i> , 2019, 10, 2160-2175.	1.7	55
47	Functional mapping of cannabinoid receptor homologs in mammals, other vertebrates, and invertebrates. <i>Gene</i> , 2003, 312, 297-303.	1.0	53
48	Cannabinoid Receptor 2 (CB ₂) Signals via G α -s and Induces IL-6 and IL-10 Cytokine Secretion in Human Primary Leukocytes. <i>ACS Pharmacology and Translational Science</i> , 2019, 2, 414-428.	2.5	49
49	Induction of Krox-24 by Endogenous Cannabinoid Type 1 Receptors in Neuro2A Cells Is Mediated by the MEK-ERK MAPK Pathway and Is Suppressed by the Phosphatidylinositol 3-Kinase Pathway. <i>Journal of Biological Chemistry</i> , 2006, 281, 29085-29095.	1.6	48
50	Real-time profiling of NK cell killing of human astrocytes using xCELLigence technology. <i>Journal of Neuroscience Methods</i> , 2011, 200, 173-180.	1.3	48
51	Cannabinoids stimulate prostaglandin production by human gestational tissues through a tissue- and CB1-receptor-specific mechanism. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008, 294, E352-E356.	1.8	47
52	Affinity and Efficacy Studies of Tetrahydrocannabinolic Acid A at Cannabinoid Receptor Types One and Two. <i>Cannabis and Cannabinoid Research</i> , 2017, 2, 87-95.	1.5	47
53	Altered Amygdala Excitation and CB1 Receptor Modulation of Aggressive Behavior in the Neuroligin-3R451C Mouse Model of Autism. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 234.	1.8	45
54	Synthesis and pharmacology of new psychoactive substance 5F μ -PICA, a scaffold-hopping analog of synthetic cannabinoid receptor agonists 5F μ -PICA and 5F μ -PINACA. <i>Drug Testing and Analysis</i> , 2019, 11, 279-291.	1.6	45

#	ARTICLE	IF	CITATIONS
55	A shifted repertoire of endocannabinoid genes in the zebrafish (<i>Danio rerio</i>). <i>Molecular Genetics and Genomics</i> , 2007, 277, 555-570.	1.0	40
56	Do Toxic Synthetic Cannabinoid Receptor Agonists Have Signature in Vitro Activity Profiles? A Case Study of AMB-FUBINACA. <i>ACS Chemical Neuroscience</i> , 2019, 10, 4350-4360.	1.7	39
57	Misidentification of prostamides as prostaglandins. <i>Journal of Lipid Research</i> , 2005, 46, 1364-1368.	2.0	36
58	A novel population of progenitor cells expressing cannabinoid receptors in the subependymal layer of the adult normal and Huntington's disease human brain. <i>Journal of Chemical Neuroanatomy</i> , 2006, 31, 210-215.	1.0	36
59	Localisation of the adenosine uptake site in the human brain: a comparison with the distribution of adenosine A1 receptors. <i>Brain Research</i> , 1996, 710, 79-91.	1.1	35
60	The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities. <i>Forensic Toxicology</i> , 2016, 34, 286-303.	1.4	35
61	Simultaneous analysis of 29 synthetic cannabinoids and metabolites, amphetamines, and cannabinoids in human whole blood by liquid chromatography-tandem mass spectrometry: A New Zealand perspective of use in 2018. <i>Drug Testing and Analysis</i> , 2020, 12, 195-214.	1.6	35
62	Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists. <i>Biochemical Pharmacology</i> , 2020, 175, 113871.	2.0	35
63	100 years of modelling ligand-receptor binding and response: A focus on GPCRs. <i>British Journal of Pharmacology</i> , 2020, 177, 1472-1484.	2.7	33
64	CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor Agonist. <i>Frontiers in Pharmacology</i> , 2019, 10, 595.	1.6	32
65	Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington's disease brain. <i>Journal of Chemical Neuroanatomy</i> , 2014, 59-60, 62-71.	1.0	31
66	c-fos antisense reduces expression of Krox 24 in rat caudate and neocortex. <i>Cellular and Molecular Neurobiology</i> , 1994, 14, 395-405.	1.7	30
67	Induction of the Krox 24 transcription factor in striosomes by a cannabinoid agonist. <i>NeuroReport</i> , 1995, 6, 241-245.	0.6	29
68	Distinct Temporal Fingerprint for Cyclic Adenosine Monophosphate (cAMP) Signaling of Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid Receptors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 5979-5988.	2.9	28
69	Nuclear Localisation of the Endocannabinoid Metabolizing Enzyme Fatty Acid Amide Hydrolase (FAAH) in Invasive Trophoblasts and an Association with Recurrent Miscarriage. <i>Placenta</i> , 2008, 29, 970-975.	0.7	27
70	A NOVEL HIGH-THROUGHPUT ASSAY FOR THE QUANTITATIVE ASSESSMENT OF RECEPTOR TRAFFICKING. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008, 35, 1377-1382.	0.9	26
71	Effects of the Parkinsonian toxin MPP+ on electrophysiological properties of nigral dopaminergic neurons. <i>NeuroToxicology</i> , 2014, 45, 1-11.	1.4	26
72	Structure-activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues. <i>Forensic Toxicology</i> , 2015, 33, 355-366.	1.4	26

#	ARTICLE	IF	CITATIONS
73	Functional Selectivity at Cannabinoid Receptors. <i>Advances in Pharmacology</i> , 2017, 80, 207-221.	1.2	26
74	Chromenopyrazole-based High Affinity, Selective Fluorescent Ligands for Cannabinoid Type 2 Receptor. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 209-214.	1.3	26
75	Biased agonism at the cannabinoid receptors – Evidence from synthetic cannabinoid receptor agonists. <i>Cellular Signalling</i> , 2021, 78, 109865.	1.7	25
76	Adenosine kinase, glutamine synthetase and EAAT2 as gene therapy targets for temporal lobe epilepsy. <i>Gene Therapy</i> , 2014, 21, 1029-1040.	2.3	24
77	Identification of <i>N</i> -arachidonoyl dopamine as a highly biased ligand at cannabinoid CB ₁ receptors. <i>British Journal of Pharmacology</i> , 2016, 173, 115-127.	2.7	23
78	One for the Price of Two – Are Bivalent Ligands Targeting Cannabinoid Receptor Dimers Capable of Simultaneously Binding to both Receptors?. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 353-363.	4.0	23
79	Characterization of Ntera2/D1 cells as a model system for the investigation of cannabinoid function in human neurons and astrocytes. <i>Journal of Neuroscience Research</i> , 2011, 89, 1685-1697.	1.3	22
80	Do you feel it now? Route of administration and ¹⁹ T-tetrahydrocannabinol-like discriminative stimulus effects of synthetic cannabinoids in mice. <i>NeuroToxicology</i> , 2019, 73, 161-167.	1.4	21
81	Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines. <i>Frontiers in Pharmacology</i> , 2018, 9, 1202.	1.6	20
82	Model-free and kinetic modelling approaches for characterising non-equilibrium pharmacological pathway activity: Internalisation of cannabinoid CB ₁ receptors. <i>British Journal of Pharmacology</i> , 2019, 176, 2593-2607.	2.7	20
83	Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias. <i>Neuropharmacology</i> , 2021, 193, 108611.	2.0	20
84	High throughput quantification of mutant huntingtin aggregates. <i>Journal of Neuroscience Methods</i> , 2008, 171, 174-179.	1.3	18
85	An evaluation of the operational model when applied to quantify functional selectivity. <i>British Journal of Pharmacology</i> , 2018, 175, 1654-1668.	2.7	18
86	The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5Fâ€‘PICA, 5Fâ€‘PINACA, and their analogs. <i>Drug Testing and Analysis</i> , 2019, 11, 976-989.	1.6	17
87	The therapeutic potential of G-protein coupled receptors in Huntington's disease. , 2010, 128, 305-323.		15
88	Alkyl indole-based cannabinoid type 2 receptor tools: Exploration of linker and fluorophore attachment. <i>European Journal of Medicinal Chemistry</i> , 2018, 145, 770-789.	2.6	15
89	Chapter 4 Anandamide Receptor Signal Transduction. <i>Vitamins and Hormones</i> , 2009, 81, 79-110.	0.7	14
90	M1 Muscarinic Receptor Activation Mediates Cell Death in M1-HEK293 Cells. <i>PLoS ONE</i> , 2013, 8, e72011.	1.1	14

#	ARTICLE	IF	CITATIONS
91	Real-Time Measurement of Cannabinoid Receptor-Mediated cAMP Signaling. <i>Methods in Enzymology</i> , 2017, 593, 43-59.	0.4	14
92	Development of selective, fluorescent cannabinoid type 2 receptor ligands based on a 1,8-naphthyridin-2-(1 <i>H</i>)-one-3-carboxamide scaffold. <i>MedChemComm</i> , 2018, 9, 2055-2067.	3.5	14
93	Exploring Stereochemical and Conformational Requirements at Cannabinoid Receptors for Synthetic Cannabinoids Related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3672-3682.	1.7	14
94	Evaluation of the profiles of CB ₁ cannabinoid receptor signalling bias using joint kinetic modelling. <i>British Journal of Pharmacology</i> , 2020, 177, 3449-3463.	2.7	12
95	In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 193, 172918.	1.3	11
96	Synthetic cannabis: adverse events reported to the New Zealand Pharmacovigilance Centre. <i>Clinical Toxicology</i> , 2021, 59, 472-479.	0.8	11
97	Sulfation of the FLAG epitope is affected by co-expression of G protein-coupled receptors in a mammalian cell model. <i>Scientific Reports</i> , 2016, 6, 27316.	1.6	10
98	Is the Cannabinoid CB ₂ Receptor a Major Regulator of the Neuroinflammatory Axis of the Neurovascular Unit in Humans?. <i>Advances in Pharmacology</i> , 2017, 80, 367-396.	1.2	9
99	A novel allosteric modulator of the cannabinoid CB ₁ receptor ameliorates hyperdopaminergia endophenotypes in rodent models. <i>Neuropsychopharmacology</i> , 2021, 46, 413-422.	2.8	9
100	Sensitive and Accurate Quantification of Human Leukocyte Migration Using High-Content Discovery-1 Imaging System and ATPlite Assay. <i>Journal of Biomolecular Screening</i> , 2012, 17, 386-393.	2.6	8
101	Co-exposure of cannabinoids with amphetamines and biological, behavioural and health outcomes: a scoping review of animal and human studies. <i>Psychopharmacology</i> , 2022, 239, 1211-1230.	1.5	8
102	Delineating the interactions between the cannabinoid CB ₂ receptor and its regulatory effectors; β -arrestins and GPCR kinases. <i>British Journal of Pharmacology</i> , 2022, 179, 2223-2239.	2.7	8
103	Increasing the flexibility of the LANCE cAMP detection kit. <i>Journal of Pharmacological and Toxicological Methods</i> , 2015, 71, 42-45.	0.3	7
104	NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity?. <i>ACS Chemical Neuroscience</i> , 2021, 12, 4020-4036.	1.7	7
105	Development of 3-(4-Chlorophenyl)-1-(phenethyl)urea Analogues as Allosteric Modulators of the Cannabinoid Type-1 Receptor: RTICBM-189 is Brain Penetrant and Attenuates Reinstatement of Cocaine-Seeking Behavior. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 257-270.	2.9	7
106	Defining Steric Requirements at CB ₁ and CB ₂ Cannabinoid Receptors Using Synthetic Cannabinoid Receptor Agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1, PX-2, NNL-1, and Their Analogues. <i>ACS Chemical Neuroscience</i> , 2022, 13, 1281-1295.	1.7	6
107	Divalent cannabinoid-1 receptor ligands: A linker attachment point survey of SR141716A for development of high-affinity CB ₁ R molecular probes. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 126644.	1.0	5
108	Inconsistencies in histone acetylation patterns among different HD model systems and HD post-mortem brains. <i>Neurobiology of Disease</i> , 2020, 146, 105092.	2.1	5

#	ARTICLE	IF	CITATIONS
109	Development of positive control tissue for in situ hybridisation using Alvetex scaffolds. Journal of Neuroscience Methods, 2014, 238, 70-77.	1.3	4
110	Putative Synthetic Cannabinoids MEPIRAPIM, 5F-BEPIRAPIM (NNL-2), and Their Analogues Are T-Type Calcium Channel (Ca _v 3) Inhibitors. ACS Chemical Neuroscience, 2022, 13, 1395-1409.	1.7	4
111	The Endocannabinoid System and Human Brain Functions. , 2017, , 115-186.		3
112	An intact model for quantifying functional selectivity. Scientific Reports, 2019, 9, 2557.	1.6	3
113	Allosteric Modulation of the Cannabinoid CB1 Receptor. , 2017, , 573-583.		1
114	Exploring group size for statistical analysis of real-time signalling experiments. British Journal of Pharmacology, 2021, 178, 3997-4004.	2.7	1
115	Signaling and Regulation of the Cannabinoid CB 1 Receptor. , 2017, , 564-572.		0
116	Covalent cannabinoid receptor ligands – structural insight and selectivity challenges. RSC Medicinal Chemistry, 0, , .	1.7	0